Airain ltd acquired a new position in shares of Alkermes Plc (NASDAQ:ALKS) during the first quarter, according to its most recent 13F filing with the SEC. The fund acquired 82,954 shares of the company’s stock, valued at approximately $4,853,000.
Other large investors have also recently made changes to their positions in the company. Norges Bank purchased a new stake in shares of Alkermes Plc during the fourth quarter worth about $44,274,000. Jennison Associates LLC purchased a new stake in shares of Alkermes Plc during the first quarter worth about $24,100,000. Marshall Wace LLP raised its stake in shares of Alkermes Plc by 100.5% in the fourth quarter. Marshall Wace LLP now owns 639,670 shares of the company’s stock worth $35,553,000 after buying an additional 320,697 shares in the last quarter. Scout Investments Inc. purchased a new stake in shares of Alkermes Plc during the third quarter worth about $14,117,000. Finally, D. E. Shaw & Co. Inc. raised its stake in shares of Alkermes Plc by 18.8% in the third quarter. D. E. Shaw & Co. Inc. now owns 1,665,836 shares of the company’s stock worth $78,345,000 after buying an additional 264,019 shares in the last quarter. 95.52% of the stock is owned by hedge funds and other institutional investors.
Shares of Alkermes Plc (NASDAQ:ALKS) traded down 0.03% on Friday, reaching $57.91. 728,646 shares of the company’s stock traded hands. The stock’s market capitalization is $8.87 billion. Alkermes Plc has a 52 week low of $39.65 and a 52 week high of $62.50. The stock’s 50-day moving average price is $57.81 and its 200-day moving average price is $56.90.
Alkermes Plc (NASDAQ:ALKS) last issued its earnings results on Thursday, April 27th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.24) by $0.07. Alkermes Plc had a negative return on equity of 12.75% and a negative net margin of 36.92%. The firm had revenue of $191.80 million for the quarter, compared to analysts’ expectations of $195.79 million. During the same quarter in the previous year, the firm posted ($0.16) EPS. The firm’s revenue for the quarter was up 22.3% compared to the same quarter last year. Equities analysts predict that Alkermes Plc will post ($0.04) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://transcriptdaily.com/2017/05/20/82954-shares-in-alkermes-plc-alks-acquired-by-airain-ltd.html.
ALKS has been the subject of a number of analyst reports. Cowen and Company reissued a “positive” rating and issued a $65.00 price objective on shares of Alkermes Plc in a report on Tuesday, March 21st. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $51.00 target price on shares of Alkermes Plc in a research note on Thursday, March 16th. JPMorgan Chase & Co. set a $78.00 target price on shares of Alkermes Plc and gave the stock a “buy” rating in a research note on Thursday, April 27th. Jefferies Group LLC reaffirmed a “buy” rating and set a $70.00 target price on shares of Alkermes Plc in a research note on Monday, April 3rd. Finally, TheStreet raised shares of Alkermes Plc from a “d+” rating to a “c” rating in a research note on Wednesday, February 15th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $63.55.
In other news, Director Robert A. Breyer sold 4,000 shares of the business’s stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $60.00, for a total transaction of $240,000.00. Following the completion of the sale, the director now owns 7,156 shares in the company, valued at approximately $429,360. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Shane Cooke sold 20,000 shares of the business’s stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $60.00, for a total value of $1,200,000.00. Following the sale, the insider now owns 73,068 shares of the company’s stock, valued at approximately $4,384,080. The disclosure for this sale can be found here. Insiders have sold a total of 199,800 shares of company stock valued at $11,638,101 in the last quarter. Company insiders own 4.75% of the company’s stock.
About Alkermes Plc
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes Plc and related companies with MarketBeat.com's FREE daily email newsletter.